Andrew Stone

5.3k total citations · 2 hit papers
59 papers, 2.9k citations indexed

About

Andrew Stone is a scholar working on Statistics and Probability, Oncology and Cancer Research. According to data from OpenAlex, Andrew Stone has authored 59 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Statistics and Probability, 10 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Andrew Stone's work include Statistical Methods in Clinical Trials (11 papers), Cancer Genomics and Diagnostics (8 papers) and Renal Diseases and Glomerulopathies (5 papers). Andrew Stone is often cited by papers focused on Statistical Methods in Clinical Trials (11 papers), Cancer Genomics and Diagnostics (8 papers) and Renal Diseases and Glomerulopathies (5 papers). Andrew Stone collaborates with scholars based in United Kingdom, United States and Australia. Andrew Stone's co-authors include Elizabeth A. Musgrove, Robert L. Sutherland, C. Elizabeth Caldon, Jane Barraclough, Richard B. Lipton, Walter F. Stewart, Miguel J. A. Láinez, J. Sawyer, Martin Jenkins and Christopher Jennison and has published in prestigious journals such as The Lancet, JAMA and Nature Communications.

In The Last Decade

Andrew Stone

52 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cyclin D as a therapeutic target in cancer

2011 1.1k citations Elizabeth A. Musgrove, C. Elizabeth Caldon et al. profile →
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

2023 121 citations Richard Lafayette, Jens Kristensen et al. profile →

Peers

Countries citing papers authored by Andrew Stone

Since Specialization

Citations

This map shows the geographic impact of Andrew Stone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Stone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Stone more than expected).

Fields of papers citing papers by Andrew Stone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Stone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Stone. The network helps show where Andrew Stone may publish in the future.

Co-authorship network of co-authors of Andrew Stone

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Stone. A scholar is included among the top collaborators of Andrew Stone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Stone. Andrew Stone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population 2024 ·Clinical Kidney Journal ·Jonathan Barratt, Andrew Stone, Heather N. Reich, Richard Lafayette	2
2	Combination CPAP and bilateral hypoglossal nerve stimulation for obstructive sleep apnea in Treacher Collins syndrome: first case report 2022 ·Journal of Clinical Sleep Medicine ·(unknown), Andrew Jones, Andrew Stone, Stuart G. MacKay	1
3	One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy 2022 ·Kidney International Reports ·Richard Lafayette, Heather N. Reich, Andrew Stone, Jonathan Barratt	8
4	329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab 2020 ·SHILAP Revista de lepidopterología ·Tom Lillie, Andrew Stone, (unknown), R. H. Brown, Andrew J. Fox, Eirini Bournazou, John Beadle	2
5	The NefIgArd trial: The Effect of Nefecon® (Budesonide) in Patients with Primary IgA Nephropathy at Risk of Developing ESRD 2020 ·Journal of the American Society of Nephrology ·Jonathan Barratt, Jens Kristensen, Andrew Stone	1
6	MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer 2019 ·British Journal of Cancer ·Michael J. G. Milevskiy, (unknown), (unknown), Andrew Stone, Korinne Northwood, Leslie Burke, Julia M.W. Gee, Kenneth P. Nephew, Susan J. Clark, Melissa A. Brown	29
7	The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design 2018 ·European Journal of Human Genetics ·Paul Lacaze, Mark Pinese, Warren Kaplan, Andrew Stone, Marie‐Jo Brion, Robyn L. Woods, Martin McNamara, John J. McNeil, Marcel E. Dinger, David M. Thomas	19
8	Long-range regulators of the lncRNAHOTAIRenhance its prognostic potential in breast cancer 2016 ·Human Molecular Genetics ·Michael J. G. Milevskiy, Fares Al‐Ejeh, Jodi M. Saunus, Korinne Northwood, Peter J. Bailey, Joshua A. Betts, Amy E. McCart Reed, Kenneth P. Nephew, Andrew Stone, Julia M.W. Gee, Dennis H. Dowhan, Eloïse Dray, Annette M. Shewan, Juliet D. French, Stacey L. Edwards, Susan J. Clark, Sunil R. Lakhani, Melissa A. Brown	58
9	Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis 2015 ·Clinical Epigenetics ·Warwick J. Locke, Elena Zotenko, Clare Stirzaker, Mark D. Robinson, Rebecca A. Hinshelwood, Andrew Stone, Roger R. Reddel, Lily I. Huschtscha, Susan J. Clark	24
10	BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer 2013 ·Molecular Cancer Therapeutics ·Andrew Stone, Mark J. Cowley, Fátima Valdés‐Mora, Rachael A. McCloy, C. Marcelo Sergio, David Gallego‐Ortega, C. Elizabeth Caldon, Christopher J. Ormandy, Andrew V. Biankin, Julia M.W. Gee, Robert I. Nicholson, Cristin G. Print, Susan J. Clark, Elizabeth A. Musgrove	39
11	Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells 2012 ·Molecular Cancer Therapeutics ·C. Elizabeth Caldon, C. Marcelo Sergio, Jian Kang, Anita Muthukaruppan, (unknown), Andrew Stone, Jane Barraclough, (unknown), Michael A. Black, Lance D. Miller, Julia M.W. Gee, (unknown), Robert L. Sutherland, Cristin G. Print, Elizabeth A. Musgrove	125
12	Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics 2012 ·Critical Reviews™ in Oncogenesis ·Andrew Stone, Robert L. Sutherland, Elizabeth A. Musgrove	48
13	Central hyperexcitability as measured with nociceptive flexor reflex threshold in chronic musculoskeletal pain: A systematic review 2011 ·Pain ·Edwin Choon Wyn Lim, Michele Sterling, Andrew Stone, Bill Vicenzino	62
14	An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints† 2010 ·Pharmaceutical Statistics ·Martin Jenkins, Andrew Stone, Christopher Jennison	140
15	The application of bespoke spending functions in group‐sequential designs and the effect of delayed treatment switching in survival trials 2009 ·Pharmaceutical Statistics ·Andrew Stone	0
16	Comparative study into the robustness of compartmental modeling and model‐free analysis in DCE‐MRI studies 2006 ·Journal of Magnetic Resonance Imaging ·Caleb Roberts, (unknown), Andrew Stone, Alan Jackson, John C. Waterton, Geoff J.M. Parker	124
17	Optimizing randomized phase II trials assessing tumor progression 2006 ·Contemporary Clinical Trials ·Andrew Stone, Catherine Wheeler, Kevin Carroll, Alan Barge	19
18	Output Gaps In Real Time: How Reliable Are They? 2005 ·Economic Record ·David Gruen, Tim Robinson, Andrew Stone	14
19	How Should Monetary Policy Respond to Asset-Price Bubbles? 2003 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·David Gruen, (unknown), Andrew Stone	43
20	Denial : a clarification of concepts and research 1989 ·Plenum Press eBooks ·E. L. Edelstein, DONALD L. NATHANSON, Andrew Stone	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact